Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Deloitte
Colorcon
Merck
Fish and Richardson
Johnson and Johnson
US Army
McKesson
Julphar

Generated: December 15, 2018

DrugPatentWatch Database Preview

ZEVALIN Drug Profile

« Back to Dashboard

Summary for Tradename: ZEVALIN

US Patents for ZEVALIN

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19 ➤ Try a Free Trial Bayer Intellectual Property GMBH (Monheim, DE) ➤ Try a Free Trial RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19 ➤ Try a Free Trial LegoChem Biosciences, Inc. (Daejeon, KR) ➤ Try a Free Trial RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19 ➤ Try a Free Trial The Regents of the University of California (Oakland, CA) ➤ Try a Free Trial RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19 ➤ Try a Free Trial ➤ Try a Free Trial RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19 ➤ Try a Free Trial Plexxikon Inc. (Berkeley, CA) ➤ Try a Free Trial RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19 ➤ Try a Free Trial AUGUSTA PHARMACEUTICALS INC. (Newton, MA) ➤ Try a Free Trial RX Orphan search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for ZEVALIN

Supplementary Protection Certificates for ZEVALIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00043 Denmark ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMAB OG REKOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: C(20135603) /EU/1/00/145/002 20130826
2016022 Lithuania ➤ Try a Free Trial PRODUCT NAME: RITUKSIMABAS; REGISTRATION NO/DATE: EU/1/98/067/001-002 20140321
2004000036 Germany ➤ Try a Free Trial FORMER OWNER: BIOGEN IDEC INC.(N.D.GES.D.STAATES DELAWARE), SAN DIEGO, CALIF., US
2009 00043 Denmark ➤ Try a Free Trial PRODUCT NAME: RITUXIMAB; NAT. REG. NO/DATE: EU 1/98/067/001-002 19980602; FIRST REG. NO/DATE: CH IKS 54378 01 19971127
620 Luxembourg ➤ Try a Free Trial 91620, EXPIRES: 20181112
089 Luxembourg ➤ Try a Free Trial 91089, EXPIRES: 20181112
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Accenture
Boehringer Ingelheim
Medtronic
US Army
Federal Trade Commission
Teva
Citi
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.